A citation-based method for searching scientific literature

U Mrowietz, K Kragballe, K Reich, P Spuls, C E M Griffiths, A Nast, J Franke, C Antoniou, P Arenberger, F Balieva, M Bylaite, O Correia, E Daudén, P Gisondi, L Iversen, L Kemény, M Lahfa, T Nijsten, T Rantanen, A Reich, T Rosenbach, S Segaert, C Smith, T Talme, B Volc-Platzer, N Yawalkar. Arch Dermatol Res 2011
Times Cited: 500







List of co-cited articles
590 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Global epidemiology of psoriasis: a systematic review of incidence and prevalence.
Rosa Parisi, Deborah P M Symmons, Christopher E M Griffiths, Darren M Ashcroft. J Invest Dermatol 2013
17

Secukinumab in plaque psoriasis--results of two phase 3 trials.
Richard G Langley, Boni E Elewski, Mark Lebwohl, Kristian Reich, Christopher E M Griffiths, Kim Papp, Lluís Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson,[...]. N Engl J Med 2014
14


Severe psoriasis--oral therapy with a new retinoid.
T Fredriksson, U Pettersson. Dermatologica 1978
14

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
Kenneth B Gordon, Andrew Blauvelt, Kim A Papp, Richard G Langley, Thomas Luger, Mamitaro Ohtsuki, Kristian Reich, David Amato, Susan G Ball, Daniel K Braun,[...]. N Engl J Med 2016
473
12


Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Kenneth B Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim A Papp, Howard Sofen, Lluís Puig, Peter Foley,[...]. Lancet 2018
278
12

European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC.
A Nast, P Gisondi, A D Ormerod, P Saiag, C Smith, P I Spuls, P Arenberger, H Bachelez, J Barker, E Dauden,[...]. J Eur Acad Dermatol Venereol 2015
276
11

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
Alan Menter, Alice Gottlieb, Steven R Feldman, Abby S Van Voorhees, Craig L Leonardi, Kenneth B Gordon, Mark Lebwohl, John Y M Koo, Craig A Elmets, Neil J Korman,[...]. J Am Acad Dermatol 2008
865
11

Psoriasis.
Frank O Nestle, Daniel H Kaplan, Jonathan Barker. N Engl J Med 2009
11

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth Gordon, Jolanta Weglowska, Lluis Puig, Kim Papp, Lynda Spelman, Darryl Toth, Francisco Kerdel,[...]. N Engl J Med 2015
495
10

Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey.
Mark G Lebwohl, Hervé Bachelez, Jonathan Barker, Giampiero Girolomoni, Arthur Kavanaugh, Richard G Langley, Carle F Paul, Lluís Puig, Kristian Reich, Peter C M van de Kerkhof. J Am Acad Dermatol 2014
310
10


Psoriasis.
Wolf-Henning Boehncke, Michael P Schön. Lancet 2015
10

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.
Alan Menter, Bruce E Strober, Daniel H Kaplan, Dario Kivelevitch, Elizabeth Farley Prater, Benjamin Stoff, April W Armstrong, Cody Connor, Kelly M Cordoro, Dawn M R Davis,[...]. J Am Acad Dermatol 2019
289
10

A systematic review of worldwide epidemiology of psoriasis.
I M Michalek, B Loring, S M John. J Eur Acad Dermatol Venereol 2017
382
9

From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis.
April W Armstrong, Michael P Siegel, Jerry Bagel, Erin E Boh, Megan Buell, Kevin D Cooper, Kristina Callis Duffin, Lawrence F Eichenfield, Amit Garg, Joel M Gelfand,[...]. J Am Acad Dermatol 2017
86
10

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
Craig L Leonardi, Alexa B Kimball, Kim A Papp, Newman Yeilding, Cynthia Guzzo, Yuhua Wang, Shu Li, Lisa T Dooley, Kenneth B Gordon. Lancet 2008
9


Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis.
P Gisondi, G Altomare, F Ayala, F Bardazzi, L Bianchi, A Chiricozzi, A Costanzo, A Conti, P Dapavo, C De Simone,[...]. J Eur Acad Dermatol Venereol 2017
91
9

Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology.
E Daudén, L Puig, C Ferrándiz, J L Sánchez-Carazo, J M Hernanz-Hermosa. J Eur Acad Dermatol Venereol 2016
63
14

European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.
A Nast, P I Spuls, G van der Kraaij, P Gisondi, C Paul, A D Ormerod, P Saiag, C H Smith, E Dauden, E M de Jong,[...]. J Eur Acad Dermatol Venereol 2017
82
10

National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study.
Rosa Parisi, Ireny Y K Iskandar, Evangelos Kontopantelis, Matthias Augustin, Christopher E M Griffiths, Darren M Ashcroft. BMJ 2020
165
9

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Christopher E M Griffiths, Kristian Reich, Mark Lebwohl, Peter van de Kerkhof, Carle Paul, Alan Menter, Gregory S Cameron, Janelle Erickson, Lu Zhang, Roberta J Secrest,[...]. Lancet 2015
553
8

Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).
A Blauvelt, J C Prinz, A B Gottlieb, K Kingo, H Sofen, M Ruer-Mulard, V Singh, R Pathan, C Papavassilis, S Cooper. Br J Dermatol 2015
229
8

Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).
C Paul, J-P Lacour, L Tedremets, K Kreutzer, S Jazayeri, S Adams, C Guindon, R You, C Papavassilis. J Eur Acad Dermatol Venereol 2015
211
8

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
Kristian Reich, Kim A Papp, Andrew Blauvelt, Stephen K Tyring, Rodney Sinclair, Diamant Thaçi, Kristine Nograles, Anish Mehta, Nicole Cichanowitz, Qing Li,[...]. Lancet 2017
288
8

Psoriasis: epidemiology, clinical features, and quality of life.
R G B Langley, G G Krueger, C E M Griffiths. Ann Rheum Dis 2005
500
8

French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults.
F Amatore, A-P Villani, M Tauber, M Viguier, B Guillot. J Eur Acad Dermatol Venereol 2019
78
10

Treatment Approaches to Moderate to Severe Psoriasis.
Paolo Gisondi, Micol Del Giglio, Giampiero Girolomoni. Int J Mol Sci 2017
58
13

European S3-guidelines on the systemic treatment of psoriasis vulgaris.
D Pathirana, A D Ormerod, P Saiag, C Smith, P I Spuls, A Nast, J Barker, J D Bos, G-R Burmester, S Chimenti,[...]. J Eur Acad Dermatol Venereol 2009
498
8


Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study.
Kenneth B Gordon, Richard G Langley, Craig Leonardi, Darryl Toth, M Alan Menter, Sewon Kang, Michael Heffernan, Bruce Miller, Regina Hamlin, Liberata Lim,[...]. J Am Acad Dermatol 2006
382
7

How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review.
Phyllis I Spuls, Lidian L A Lecluse, Marie-Louise N F Poulsen, Jan D Bos, Robert S Stern, Tamar Nijsten. J Invest Dermatol 2010
153
7

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2).
Alice B Gottlieb, Andrew Blauvelt, Diamant Thaçi, Craig L Leonardi, Yves Poulin, Janice Drew, Luke Peterson, Catherine Arendt, Daniel Burge, Kristian Reich. J Am Acad Dermatol 2018
91
7

Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies.
Alan Menter, Neil J Korman, Craig A Elmets, Steven R Feldman, Joel M Gelfand, Kenneth B Gordon, Alice Gottlieb, John Y M Koo, Mark Lebwohl, Henry W Lim,[...]. J Am Acad Dermatol 2009
306
7

Psoriasis and comorbid diseases: Epidemiology.
Junko Takeshita, Sungat Grewal, Sinéad M Langan, Nehal N Mehta, Alexis Ogdie, Abby S Van Voorhees, Joel M Gelfand. J Am Acad Dermatol 2017
404
7


British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017.
C H Smith, Z K Jabbar-Lopez, Z Z Yiu, T Bale, A D Burden, L C Coates, M Cruickshank, T Hadoke, E MacMahon, R Murphy,[...]. Br J Dermatol 2017
143
7

Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council.
Bruce Strober, Caitriona Ryan, Peter van de Kerkhof, Joelle van der Walt, Alexa B Kimball, Jonathan Barker, Andrew Blauvelt. J Am Acad Dermatol 2020
48
14

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Diamant Thaçi, Andrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, Francisco Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Sophie Hugot, Ruquan You,[...]. J Am Acad Dermatol 2015
360
7

Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.
Alan Menter, Neil J Korman, Craig A Elmets, Steven R Feldman, Joel M Gelfand, Kenneth B Gordon, Alice Gottlieb, John Y M Koo, Mark Lebwohl, Craig L Leonardi,[...]. J Am Acad Dermatol 2011
320
7

Think beyond the Skin: 2014 Canadian Expert Opinion Paper on Treating to Target in Plaque Psoriasis.
Wayne Gulliver, Charles Lynde, Jan P Dutz, Ronald B Vender, Jensen Yeung, Marc Bourcier, Pierre-Luc Dion, Chi-Ho Hong, Gordon Searles, Yves Poulin. J Cutan Med Surg 2015
18
33

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
Alan Menter, Stephen K Tyring, Kenneth Gordon, Alexa B Kimball, Craig L Leonardi, Richard G Langley, Bruce E Strober, Martin Kaul, Yihua Gu, Martin Okun,[...]. J Am Acad Dermatol 2008
631
6

Psoriasis prevalence among adults in the United States.
Tara D Rachakonda, Clayton W Schupp, April W Armstrong. J Am Acad Dermatol 2014
491
6

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.
K A Papp, K Reich, C Paul, A Blauvelt, W Baran, C Bolduc, D Toth, R G Langley, J Cather, A B Gottlieb,[...]. Br J Dermatol 2016
285
6

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
Kim A Papp, Richard G Langley, Mark Lebwohl, Gerald G Krueger, Philippe Szapary, Newman Yeilding, Cynthia Guzzo, Ming-Chun Hsu, Yuhua Wang, Shu Li,[...]. Lancet 2008
6

The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
K Reich, M Gooderham, L Green, A Bewley, Z Zhang, I Khanskaya, R M Day, J Goncalves, K Shah, V Piguet,[...]. J Eur Acad Dermatol Venereol 2017
93
6



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.